Statements (35)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:approvalYear |
2009
|
| gptkbp:approvedBy |
gptkb:European_Union
gptkb:United_States |
| gptkbp:ATCCode |
L01XC10
|
| gptkbp:brand |
gptkb:Kesimpta
Arzerra |
| gptkbp:CASNumber |
679818-59-8
|
| gptkbp:developer |
gptkb:Novartis
gptkb:Genmab GlaxoSmithKline |
| gptkbp:eliminationHalfLife |
14 days
|
| gptkbp:hasMolecularFormula |
C6488H10008N1736O2023S42
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ofatumumab
|
| gptkbp:KEGGID |
D08913
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
binds to CD20 on B lymphocytes
|
| gptkbp:molecularWeight |
146 kDa
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:PubChem_CID |
CHEMBL1201836
DB06650 |
| gptkbp:routeOfAdministration |
subcutaneous
intravenous |
| gptkbp:sideEffect |
gptkb:anemia
infections neutropenia thrombocytopenia infusion reactions |
| gptkbp:target |
gptkb:CD20
|
| gptkbp:UNII |
JX8WYN7B5A
|
| gptkbp:usedFor |
multiple sclerosis
chronic lymphocytic leukemia |
| gptkbp:bfsParent |
gptkb:Genmab
gptkb:Genmab_A/S |
| gptkbp:bfsLayer |
7
|